Recently, the highly anticipated 2025 China Biomedical Industry Front Runners100 List was grandly released at the 2025 Shanghai Biomedical Investment and Financing Summit & Fudan Biomedical Innovation and Development Forum. Leveraging its globally leading innovative original technology platforms in the field of cell and gene therapy, as well as core product pipelines with global first-in-class (FIC) and best-in-class (BIC) potential, Juncell Therapeutics stood out among numerous enterprises and has been re-selected onto the list for three consecutive years.

Initiated by the Shanghai Biomedical Science and Technology Industry Promotion Center, the China Biomedical Industry Front Runners 100 List aims to identify forward-looking trends and explore cutting-edge technologies, serving as a wind vane for industrial development. Through multiple rounds of rigorous evaluation, benchmark enterprises in various sectors have been selected, marking that China's biomedical industry has shifted from extensive innovation to an era of high-quality and selective innovation. 

As a contributor to the times, we need uphold innovation and pursue excellence. Committed to the craftsmanship of refining cells to develop products and the responsibility of safeguarding life to repay society, Juncell Therapeutics will bring the warmth of technology to every patient in need. With innovation as its core engine, the Company will inject sustained impetus into China's biomedical industry's leap from following to leading.